NCT01131195 is a Phase 3 clinical trial of bevacizumab, Paclitaxel in Breast Cancer, sponsored by Swiss Cancer Institute.

Who is sponsoring NCT01131195?

NCT01131195 is sponsored by Swiss Cancer Institute.

What drugs are being tested in NCT01131195?

Interventions in NCT01131195: bevacizumab, Paclitaxel, Bevacizumab, Cyclophosphamide, Capecitabine.

What condition does NCT01131195 study?

NCT01131195 studies Breast Cancer.

Is NCT01131195 still recruiting?

NCT01131195 is currently completed. Last updated 15 May 2019.

Last reviewed 2019-05-15 · How we verify

NCT01131195

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metronomic Therapy in Metastatic Breast Cancer.

Completed Phase 3 Last updated 15 May 2019

What this trial tests

Phase 3 trial testing bevacizumab, Paclitaxel in Breast Cancer in 139 participants. Completed in 28 February 2018.

Timeline

19 July 2010

Primary endpoint
14 December 2012

28 February 2018

Quick facts

Lead sponsor	Swiss Cancer Institute
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	139
Start date	19 July 2010
Primary completion	14 December 2012
Estimated completion	28 February 2018
Sites	23 locations across Switzerland

Drugs / interventions tested

bevacizumab, Paclitaxel — full drug profile →
Bevacizumab, Cyclophosphamide, Capecitabine — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Swiss Cancer Institute

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as paclitaxel, cyclophosphamide, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether bevacizumab is more effective when given together with paclitaxel or cyclophosphamide and capecitabine in treating patients with breast cancer. PURPOSE: This randomized phase III trial is studying the side effects of giving bevacizumab together with paclitaxel and to see how well it works compared with giving bevacizumab together with cyclophosphamide and capecitabine as first-line therapy in treating women with locally advanced, recurrent, or metastatic breast cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Mouse models of advanced spontaneous metastasis for experimental therapeutics.
Francia G, Cruz-Munoz W, Man S, Xu P, et al · · 2011 · cited 283× · PMID 21258397 · DOI 10.1038/nrc3001
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
Hackl C, Man S, Francia G, Milsom C, et al · · 2013 · cited 77× · PMID 22543158 · DOI 10.1136/gutjnl-2011-301585
Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.
Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, et al · · 2012 · cited 71× · PMID 23008712 · DOI 10.1155/2012/417673
A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
Guerin E, Man S, Xu P, Kerbel RS. · · 2013 · cited 70× · PMID 23610448 · DOI 10.1158/0008-5472.can-12-4183
Reappraising antiangiogenic therapy for breast cancer.
Kerbel RS. · · 2011 · cited 50× · PMID 22015294 · DOI 10.1016/s0960-9776(11)70295-8
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C, Bigler M, von Moos R, Bernhard J, et al · · 2016 · cited 42× · PMID 27724870 · DOI 10.1186/s12885-016-2823-y
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology.
Jan N, Sofi S, Qayoom H, Shabir A, et al · · 2024 · cited 26× · PMID 38314272 · DOI 10.1016/j.heliyon.2024.e24670
Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.
Pasquier E, Kieran MW, Sterba J, Shaked Y, et al · · 2011 · cited 25× · PMID 21804915 · DOI 10.1593/tlo.11124

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Swiss Cancer Institute trials

Trials by the same sponsor.

NCT07158489 — Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC · Phase 2 · not yet recruiting
NCT06835049 — Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue · Phase 2 · recruiting
NCT06452394 — NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline · Phase 2 · recruiting
NCT06114108 — Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients · NA · recruiting
NCT04629781 — Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01131195 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Cancer Institute
Last refreshed: 15 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01131195.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing